PROVE-IT TIMI 22

OBJECTIVE: To compare the efficacy of atorvastatin vs. pravastatin and the clinical efficacy of the antibiotic gatifloxacin vs. placebo in a 2 x 2 factorial design among patients presenting with unstable angina or non-Q-wave myocardial infarction.

View/Download
_______________________________________________________________________________

  1. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Cannon CP, McCabe CH, Belder R, Breen J, Braunwald E. Am J Cardiol 2002;89:860-1.
    | Abstract | Request Reprints |

  2. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. Cannon CP, Braunwald E, McCabe CH, et al. N Engl J Med 2004;350:1495-504.
    | Abstract | Request Reprints |

  3. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction (PROVE IT - TIMI) 22 Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlstein B, Giugliano RP, Cairns R, Skene AM Investigators. N Engl J Med 2005;352:1646-54.
    | Abstract | Request Reprints |


  4. Graded benefit of atorvastatin over pravastatin dependent upon baseline LDL. Giugliano RP, Cannon CP, Rader D, Grundy SM, McCabe CH, Braunwald E. Circulation 2004;110:III-696.
    | Request Reprints |

  5. Association of intensive lipid lowering with reductions in target vessel revascularization (clinical restenosis) and non-target vessel revascularization (lesion progression): a PROVE-IT TIMI 22 substudy. Gibson CM, Sabatine MS, Murphy SA, Morrow DA, Wiviott SD, Smith S, McCabe CH, Cannon CP, Braunwald E. Circulation 2004;110:III-696.
    | Request Reprints |

  6. High-dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy. Sabatine MS, Wiviott SD, Morrow DA, McCabe CH, Cannon CP. Circulation 2004;110, (Suppl III):III-834.
    | Request Reprints |

  7. Does Intensive statin therapy reduce both urgent and elective coronary revascularization? Results from PROVE-IT TIMI 22. Sabatine MS, Morrow DA, McCabe CH, Smith S, Meredtih I, de Ferrari G, Gibson CM. Circulation 2004;110, (Suppl III):III-696.
    | Request Reprints |

  8. Seasonal variations in lipid values in patients following acute coronary syndrome: PROVE IT–TIMI 22.Wiviott SD, Cannon CP, Ray KK, Murphy SA, Darius H, Castaigne A, Velasco JA, McCabe CH, Gibson CM. J Am Coll Cardiol 2005; 45(3 Suppl A):394A.
    | Request Reprints |

  9. Baseline urinary albumin concentration predicts long-term cardiovascular risk in acute coronary syndrome patients: A PROVE IT-TIMI 22 substudy. Ray KK, Morrow DA, Murphy SA, McCabe CH, Gibson CM, Cannon CP. J Am Coll Cardiol 2005; 45(3 Suppl A):195A.
    | Request Reprints |

  10. Dramatic benefit of intensive statin therapy in women: Results from PROVE IT – TIMI 22. Rose E, McCabe C, Cairns R, Cannon CP, Braunwald E. J Am Coll Cardiol 2005;45:12A.
    | Request Reprints |

  11. Percutaneous coronary intervention for ACS is associated with a long-term reduction in CRP: An analysis from PROVE IT – TIMI 22. Ray KK, Cannon CP, Morrow DA, Cairns R, Braunwald E. Eur Heart J 2005;26(abstr):39.
    | Request Reprints |

  12. Baseline ApoB predicts benefit of intensive statin therapy in patients with ACS: An analysis from PROVE IT-TIMI 22. Ray KK, Cannon CP, Rader DJ, Cairns R, McCabe CH, Sacks FM, Braunwald E. Eur Heart J 2005;26(abstr):553.
    | Request Reprints |

  13. Acute coronary syndromes and diabetes mellitus: Does intensive lipid lowering work? Ahmed S, Cannon CP, McCabe CH, Murphy SA, Braunwald E. Eur Heart J 2005;26(abstr):666.
    | Request Reprints |

  14. CRP is additive and independent of Apo B/A1 ratio in explaining the clinical benefits of atorvastatin 80 mg in ACS patients in PROVE IT – TIMI 22.Ray KK, Cannon CP, Morrow DA, Cairns R, McCabe CH, Ridker PM, Braunwald E. Circulation 2005;112:II:483.
    | Request Reprints |

  15. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E. J Am Coll Cardiol 2005;46:1411-6.
    | Abstract | Request Reprints |

  16. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. Ray KK, Cannon CP, Cairns R, et al. J Am Coll Cardiol 2005;46:1417-24.
    | Abstract | Request Reprints |

  17. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E. J Am Coll Cardiol 2005;46:1411-6.
    | Abstract | Request Reprints |

  18. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. Ray KK, Cannon CP, McCabe CH, et al. J Am Coll Cardiol 2005;46:1405-10.
    | Abstract | Request Reprints |

  19. C-reactive protein levels and outcomes after statin therapy. Ridker PM, Cannon CP, Morrow D, et al. N Engl J Med 2005;352:20-8.
    | Abstract | Request Reprints |

  20. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. J Am Coll Cardiol 2005;45:1644-8.
    | Abstract | Request Reprints |

  21. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. Ray KK, Cannon CP, Cairns R, et al. J Am Coll Cardiol 2005;46:1417-24.
    | Abstract | Request Reprints |

  22. Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. Mega JL, Morrow DA, Cannon CP, et al. J Thromb Thrombolysis 2006;22:71-6.
    | Abstract | Request Reprints |

  23. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Ray KK, Bach RG, Cannon CP, et al. Eur Heart J 2006;27:2310-6.
    | Abstract | Request Reprints |

  24. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. O'Donoghue M, Morrow DA, Sabatine MS, et al. Circulation 2006;113:1745-52.
    | Abstract | Request Reprints |

  25. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. Scirica BM, Morrow DA, Cannon CP, et al. J Am Coll Cardiol 2006;47:2326-31.
    | Abstract | Request Reprints |

  26. Elevated Levels of Placental Growth Factor (PlGF) and Long Term Risk in Patients in Acute Coronary Syndromes in PROVE IT-TIMI 22. Bonaca MP, Morrow DA, Sabatine MS, Kausik KR, Rifai N, Cannon CP. Circulation 2006 114; 18 (Supp) II-649
    | Request Reprints |

  27. Schweiger MJ, Giugliano RP, Lotfi A, Murphy SA, Cannon CP. High dose atorvastatin does not impact the efficacy of clopidogrel - A PROVE IT TIMI-22 analysis. J Am Coll Cardiol 2006;47(4):380A.
    | Request Reprints |

  28. Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. Ahmed S, Cannon CP, Murphy SA, Braunwald E. Eur Heart J 2006;27:2323-9.
    | Abstract | Request Reprints |

  29. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Ray KK, Morrow DA, Sabatine MS, et al. Circulation 2007;115:3071-8.
    | Abstract | Request Reprints |

  30. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. J Am Coll Cardiol 2008;51:724-30.
    | Abstract | Request Reprints |

  31. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. Lotfi A, Schweiger MJ, Giugliano GR, Murphy SA, Cannon CP. Am Heart J 2008;155:954-8.
    | Abstract | Request Reprints |

  32. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Morrow DA, Wang Y, Croce K, et al. Am Heart J 2008;155:49-55.
    | Abstract | Request Reprints |

  33. Polymorphism in K1F6 gene and benefit from statins after acute coronary syndromes: Results from the PROVE IT - TIMI 22 study. Iakoubova OA, Sabatine MS, Rowland CM, Tong CH, Catanese JJ, Ranade K, Simonsen KL, Kirchgessner TG, Cannon CP, Devlin JJ, Braunwald E. J Am Coll Cardiol 2008;251:449-55.
    | Request Reprints |

  34. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. Giraldez RR, Giugliano RP, Mohanavelu S, et al. J Am Coll Cardiol 2008;52:914-20.
    | Abstract | Request Reprints |

 

 

Home | Trials | Core Laboratories | Services | Publications | Education | Funding | Contact Us |

© 2009 All Rights Reserved TIMI Study Group